Sigyn Therapeutics holder reports 9.99% stake
Sigyn Therapeutics, Inc. received an amended Schedule 13G/A showing that Brio Capital Master Fund Ltd., together with Brio Capital Management LLC, reports beneficial ownership of 160,537 shares of common stock, representing 9.99% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Sigyn Therapeutics, Inc. received an amended Schedule 13G/A showing that Brio Capital Master Fund Ltd., together with Brio Capital Management LLC, reports beneficial ownership of 160,537 shares of common stock, representing 9.99% of the class.
The filing explains that this amount includes 84,608 shares of common stock plus additional shares issuable from warrants, convertible notes and convertible preferred shares, subject to a 9.99% beneficial ownership cap. The percentage is based on 1,605,377 shares outstanding as of November 14, 2025. The reporting persons certify the holdings are not for the purpose of changing or influencing control of the company.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who is the reporting holder in the Sigyn Therapeutics (SIGY) Schedule 13G/A?
What percentage of Sigyn Therapeutics (SIGY) does Brio Capital’s holding represent?
What securities are included in Brio Capital’s reported Sigyn Therapeutics (SIGY) position?
What is the 9.99% beneficial ownership limitation mentioned for Sigyn Therapeutics (SIGY)?
Does Brio Capital seek to influence control of Sigyn Therapeutics (SIGY)?
Who signs the Sigyn Therapeutics (SIGY) Schedule 13G/A for the reporting entities?
AI-generated analysis. How Rhea-AI works. Not financial advice.